Document:

<PAGE>

                                                                    EXHIBIT 10.8

                             COLLABORATION AGREEMENT

         THIS COLLABORATION AGREEMENT (the "Agreement") is made as of February
11, 1998 (the "Effective Date"), by and between TERRAPIN TECHNOLOGIES, INC., a
Delaware corporation with its offices at 750 Gateway Boulevard, South San
Francisco, California 94080 ("Terrapin") and GENAISSANCE PHARMACEUTICALS, INC.,
a Delaware corporation with its offices at Five Science Park, New Haven,
Connecticut 06511 ("Genaissance").

                                    RECITALS

         WHEREAS, Terrapin has a proprietary technology known as TRAP-TM- (the
"TRAP-TM- Technology") and other screening and chemistry technologies and
possesses a highly diverse library (the "Terrapin Library") of small molecule
compounds (the "Terrapin Compounds") and is able to screen its library employing
such technologies;

         WHEREAS, Genaissance has the capability to harvest estrogen receptor
isogenes (variation, mutation and genome subtypes) (the "Genaissance Targets")
and express these isogenes in assays suitable for screening (the "Genaissance
Assays") against selected compounds provided by Terrapin; and

         WHEREAS, Terrapin and Genaissance desire to engage in joint research
and development in the area of selective estrogen receptor modulators (the
"Collaboration") that initially will apply the TRAP-TM- Technology to the
Terrapin Library in order to identify those Terrapin Compounds which are most
likely to show differential pharmacological activity in relation to the
Genaissance Targets and therefore may lead to candidates for pharmaceutical
development.

         NOW, THEREFORE, in consideration of the foregoing premises and the
covenants set forth below, the parties hereby agree as follows:

1.       GENERAL GENAISSANCE RESPONSIBILITIES.

         1.1 GENAISSANCE TEAM. Genaissance will provide a team, initially headed
by Dr. Christopher Hartnett and Dr. Nikolai Zvonok, to the Collaboration.

         1.2 SELECTION OF GENAISSANCE TARGETS. Genaissance will harvest a
minimum of six (6) estrogen receptor isogenes (variation, mutation and genome
subtypes) from internal discovery efforts, as well as public domain information,
and express these isogenes in assays suitable for screening. The isogenes will
be deemed to be the "Genaissance Targets" and the assays will be deemed to be
the "Genaissance Assays".

2.       GENERAL TERRAPIN RESPONSIBILITIES.

         2.1 TERRAPIN TEAM. Terrapin will provide a team, initially headed by
Dr. Reinaldo Gomez and Dr. Hugo Villar, to the Collaboration.

<PAGE>

*CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

3.       SCREENING PROGRAM.

         3.1 PROVISION OF INITIAL COMPOUNDS. Within thirty (30) days of
notification by Genaissance that it has developed each Genaissance Assay,
Terrapin shall, based upon its knowledge of the Terrapin Library and using the
TRAP-TM- Technology, select and provide Genaissance with an initial set of
approximately ************* compounds (the "Initial Compounds") from the
Terrapin Library that Terrapin believes, in its sole discretion, represent
reasonable chemical compound diversity in the Terrapin Library. The Initial
Compounds shall include *****************************.

         3.2 SCREENING OF INITIAL COMPOUNDS. Genaissance shall, within ninety
(90) days of receipt of the Initial Compounds, (i) screen each Initial Compound
for activity with respect to each Genaissance Target in the associated
Genaissance Assay and (ii) provide Terrapin with the Pharmacological Data
resulting therefrom for each of the Initial Compounds with respect to each
Genaissance Target (the "Initial Results"). For purposes of this Agreement,
"Pharmacological Data" shall mean the concentration of each compound that
elicits a **************** response in the applicable assay (the "****").

         3.3 PROVISION OF SECOND ROUND COMPOUNDS. Within thirty (30) days of
receipt of the Initial Results for a given Genaissance Target, Terrapin shall,
based upon such Initial Results and using the TRAP-TM- Technology and/or, at
Terrapin's sole discretion, any other search technology available to Terrapin,
select and provide Genaissance with a set of additional compounds (the "Second
Round Compounds") from the Terrapin Library that Terrapin believes, in its sole
discretion, will exhibit the greatest likelihood of activity in relation to such
Genaissance Target.

         3.4 SCREENING OF SECOND ROUND COMPOUNDS. Genaissance shall, within
thirty (30) days of receipt of a set of Second Round Compounds for a given
Genaissance Target, (i) screen each Second Round Compound for activity with
respect to such Genaissance Target in the associated Genaissance Assay and (ii)
provide Terrapin with the Pharmacological Data resulting therefrom for each of
the Second Round Compounds (the "Second Round Results").

         3.5 PROVISION OF THIRD ROUND COMPOUNDS. Within thirty (30) days of
receipt of the Second Round Results for a given Genaissance Target, Terrapin
shall, based upon the Initial Results and Second Round Results and using the
TRAP-TM- Technology and/or, at Terrapin's sole discretion, any other search
technology available to Terrapin, select and provide Genaissance with a set of
additional compounds (the "Third Round Compounds") from the Terrapin Library
that Terrapin believes, in its sole discretion, will exhibit the greatest
likelihood of activity in relation to such Genaissance Target.

         3.6 SCREENING OF THIRD ROUND COMPOUNDS. Genaissance shall, within
thirty (30) days of receipt of a set of Third Round Compounds for a given
Genaissance Target, (i) screen each Third Round Compound for activity with
respect to such Genaissance Target in the associated Genaissance Assay and (ii)
provide Terrapin with the Pharmacological Data resulting therefrom for each of
the Third Round Compounds.

                                       2
<PAGE>

*CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

         3.7 TOTAL COMPOUNDS; CODED FORM. A total of up to *********************
Terrapin Compounds will be provided per Genaissance Assay. All compounds
provided by Terrapin under this Article 3 shall be deemed to be Terrapin
Compounds and shall be provided in coded form. All information provided by
Genaissance to Terrapin under this Article 3 relating to the identity of the
Genaissance Targets and the Genaissance Assays shall be provided in coded form.

         3.8 TERM OF SCREENING PROGRAM. The screening program described in this
Article 3 (the "Screening Program") shall be completed during the Screening
Period. From time to time and upon completion of the Screening Program, the
parties will meet to assess the results of the Screening Program. For purposes
of this Agreement, the "Screening Period" shall mean the period commencing on
the Effective Date and terminating on the twelve (12) month anniversary of the
Effective Date, unless extended by mutual agreement of the parties.

4.       SHIPMENT OF COMPOUNDS; NO REVERSE ENGINEERING.

         4.1 DELIVERIES. All deliveries pursuant to this Agreement shall be
shipped to the address and addressee specified by the receiving party and shall
be prepaid by the shipper.

         4.2 COVENANT NOT TO REVERSE ENGINEER. Genaissance shall not attempt to
ascertain, by any means, the chemical structure or any other information
concerning any compound supplied by Terrapin hereunder unless and until Terrapin
has provided the chemical structure to Genaissance. Such covenant shall survive
during the term of this Agreement and for a period of five (5) years following
the expiration or earlier termination of this Agreement.

5.       EXPLOITATION OF DEVELOPMENTS.

         5.1 DURING COLLABORATION PERIOD.

                  5.1.1 During the Collaboration Period (as defined below), the
parties initially will work on a non-exclusive basis with one another with
respect to the Genaissance Assays and Genaissance Targets. It is presently
contemplated that such work may be converted to an exclusive basis if and when
mutually agreed to by the parties. At such time as the parties may discuss an
exclusive relationship, they will also discuss expanding the research roles of
the parties under the Collaboration.

                  5.1.2 During the Collaboration Period, the parties agree to
work together to identify one or more corporate partner(s), and will use good
faith efforts to enter into agreements with such identified corporate
partner(s), for the development and commercialization of Screening Program
Intellectual Property (as defined in Section 6.1 below), including any compounds
identified, either directly or indirectly, as a result of the Screening Program.

                  5.1.3 In the event Genaissance and Terrapin enter into
agreement with corporate partner(s) under Section 5.1.2, the parties agree to
divide all amounts received from such corporate partner(s), including, without
limitation, royalties, license fees, milestones, and equity, with each of
Genaissance and Terrapin receiving fifty percent (50%) of such amounts;
PROVIDED, HOWEVER, research revenues under any agreement with a corporate
partner will be divided on the

                                       3
<PAGE>

*CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

basis of the financial commitments for research of each party hereto under the
development program(s) with such corporate partner(s).

                  5.1.4 The "Collaboration Period" shall mean (i) the Screening
Period and (ii) if the Success Criteria (as defined below) are met by the end of
the Screening Period, the one (1) year period beginning on the last day of the
Screening Period. In the event the parties identify one or more promising
Terrapin Compounds which do not meet the Success Criteria, the parties will meet
to discuss, in good faith, extending the Collaboration Period beyond the
Screening Period.

                  5.1.5 The "Success Criteria" shall be deemed to have been met
if, after the three rounds of screening described in Article 3, (i) one or more
Terrapin Compounds provided hereunder has an ***** in a Genaissance Assay of
less than or equal to ********************* and (ii) at least one of such
Terrapin Compounds is amenable and appropriate for further chemical
optimization, based upon mutual consultation between Terrapin and Genaissance.

                  5.1.6 Within fifteen (15) days following the three rounds of
screening described in Article 3, (i) Terrapin will notify Genaissance of the
identity of the Terrapin Compounds which had an **** in a Genaissance Assay of
less than or equal to ************************ and (ii) Genaissance will notify
Terrapin of the identity of the Genaissance Assays, and related Genaissance
Targets, in which each such Terrapin Compound exhibited such activity.

                  5.1.7 As part of the collaboration, it is understood and
agreed that, during the Collaboration Period, Terrapin may, at its option and
upon consultation with Genaissance, utilize its technologies and resources,
including its employees and Scientific Advisory Board, to do further work on
promising compounds identified under the Collaboration and to report the results
of such undertaking to Genaissance. In addition, as part of the collaboration,
it is understood and agreed that, during the Collaboration Period, Genaissance
may, at its option and upon consultation with Terrapin, utilize its technologies
and resources, including its employees and Scientific Advisory Board, to do
further work on promising isogene targets and assays identified under the
Collaboration and to report the results of such undertaking to Terrapin.

         5.2 FOLLOWING COLLABORATION PERIOD. Following the Collaboration Period,
in the event the parties have not entered into an agreement with a corporate
partner under Section 5.1.2, then, subject to Article 6, the parties will be
under no obligation to collaborate further with respect to the Genaissance
Assays, the Genaissance Targets, the Terrapin Library, the Terrapin Compounds or
the TRAP-TM- Technology.

6.       OWNERSHIP OF INTELLECTUAL PROPERTY.

         6.1 DISCLOSURE OF INVENTIONS. If any employee of a party, either alone
or jointly with the other party, makes any invention or discovery (whether
patentable or not) or creates, conceives or reduces to practice any other
intellectual property (including, without limitation, any method, process, data,
information or know-how) arising as a direct result of the Screening Program
("Screening Program Intellectual Property"), such party shall promptly inform
the other party of it in writing.

                                       4
<PAGE>

         6.2 OWNERSHIP AND EXPLOITATION OF INVENTIONS. The parties will be joint
owners of any Screening Program Intellectual Property. In the event that the
parties do not enter into a broader collaboration with respect to such Screening
Program Intellectual Property, either between the two parties or with third
party corporate partner(s) under Section 5.1.2, then the parties shall consult
concerning the licensing and/or commercial exploitation of any Screening Program
Intellectual Property and neither party shall take any action or enter into any
agreements with respect thereto except pursuant to a subsequent agreement
between the parties.

         6.3 PROSECUTION OF PATENTS.

                  6.3.1 The parties shall consult in advance with respect to the
filing, prosecution and maintenance of patent applications for any Screening
Program Intellectual Property.

                  6.3.2 Unless the parties otherwise agree, Terrapin shall in
the names of Genaissance and Terrapin file, prosecute and maintain patent
applications and patents on the Screening Program Intellectual Property relating
to the use or composition of compounds throughout the world and shall pay all
costs incurred with relation to the filing, prosecution and maintenance of such
applications and patents and Genaissance will reimburse to Terrapin one half
(1/2) of such costs upon receipt of invoices therefor together with the relevant
documents which verify such invoices.

                  6.3.3 Unless the parties otherwise agree, Genaissance shall in
the names of Genaissance and Terrapin file, prosecute and maintain patent
applications and patents on the Screening Program Intellectual Property relating
to targets or assays throughout the world and shall pay all costs incurred with
relation to the filing, prosecution and maintenance of such applications and
patents and Terrapin will reimburse to Genaissance one half (1/2) of such costs
upon receipt of invoices therefor together with the relevant documents which
verify such invoices.

7.       CONFIDENTIAL INFORMATION.

         7.1 NONDISCLOSURE OBLIGATIONS. Subject to the provisions of Section 7.2
below, during the term of this Agreement and for five (5) years following its
expiration or termination, any and all knowledge, know-how, screening results,
assay information, compound structures, practices, processes or other
information received by one party to this Agreement (the "Receiving Party") from
the other party to this Agreement (the "Disclosing Party") pursuant to this
Agreement (hereinafter referred to as "Confidential Information") shall be
received and maintained by the Receiving Party in strict confidence, shall not
be disclosed to any third party except as provided in this Agreement, and shall
not be used by the Receiving Party for any purpose other than those purposes
specified in this Agreement, unless the Receiving Party can demonstrate by
competent written proof that such Confidential Information:

                           (a) was already known to the Receiving Party, other
than under an obligation of confidentiality, at the time of disclosure by the
Disclosing Party;

                           (b) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the
Receiving Party;

                                       5
<PAGE>

                           (c) became generally available to the public or
otherwise part of the public domain after its disclosure and other than through
any act of omission of the Receiving Party in breach of this Agreement;

                           (d) was disclosed to the Receiving Party, other than
under an obligation of confidentiality to a third party, by a third party who
had no obligation to the Disclosing Party not to disclose such information to
others; or

                           (e) was independently discovered or developed by the
Receiving Party without the use of Confidential Information belonging to the
Disclosing Party.

         7.2 AUTHORIZED DISCLOSURE. Each party may disclose Confidential
Information belonging to the other party to the extent such disclosure is
reasonably necessary in the following instances:

                           (a) filing or prosecuting patents relating to
Screening Program Intellectual Property;

                           (b) prosecuting or defending litigation;

                           (c) complying with applicable governmental
regulations;

                           (d) disclosure to affiliates, sublicensees,
employees, consultants, or agents each of whom is bound by similar terms of
confidentiality and non-use at least equivalent in scope to those set forth in
this Article 7; and,

                           (e) disclosure to investment bankers.

Notwithstanding the foregoing, in the event a party is required to make a
disclosure of the other party's Confidential Information pursuant to this
Section 7.2 it will, except where impracticable, give reasonable advance notice
to the other party of such disclosure and use best efforts to take all
reasonable action to avoid disclosure of Confidential Information hereunder.
Notwithstanding anything in this Agreement, in no event will Genaissance
disclose the compound structure information disclosed by Terrapin for the
Terrapin Compounds to any third party.

8.       REPRESENTATIONS; WARRANTIES; USE OF TERRAPIN COMPOUNDS.

         8.1 BY GENAISSANCE. Genaissance represents and warrants to Terrapin
that it has the right to carry out the activities set forth in this Agreement
and that it has not previously entered and will not enter during the term of
this Agreement into any agreement with a third party in conflict with this
Agreement.

         8.2 BY TERRAPIN. Terrapin represents and warrants to Genaissance that
it has the right to carry out the activities set forth in this Agreement and
that it has not previously entered and will not enter during the term of this
Agreement into any agreement with a third party in conflict with this Agreement.

                                       6
<PAGE>

         8.3 DISCLAIMER CONCERNING COMPOUNDS. THE COMPOUNDS SUPPLIED HEREUNDER
AND ANY CHEMICAL STRUCTURES DISCLOSED HEREUNDER ARE BEING SUPPLIED TO
GENAISSANCE WITH NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THEY ARE
FREE FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE
LIKE.

         8.4 USE OF TERRAPIN COMPOUNDS. Genaissance shall use the Terrapin
Compounds solely for the purposes specified in this Agreement and in compliance
with all applicable laws and regulations. Genaissance shall not sell, transfer,
disclose or otherwise provide access to the Terrapin Compounds, any method or
process relating thereto or any material that could not have been made but for
the foregoing to any person or entity without the prior express written consent
of Terrapin, except that Genaissance may allow access to the Terrapin Compounds
to employees or agents for purposes consistent with this Agreement. Genaissance
will take reasonable steps to ensure that such employees and agents will use the
Terrapin Compounds in a manner that is consistent with the terms of this
Agreement. Genaissance acknowledges and agrees that the Terrapin Compounds may
have biological and/or chemical properties that are unpredictable and unknown at
the time of transfer, that they are to be used with caution and prudence, and
are not to be used for testing in or treatment of humans or other animals.

9.       TERM; TERMINATION.

         9.1 TERM. This Agreement shall become effective as of the Effective
Date and unless earlier terminated as hereinafter provided, shall continue in
force until the end of the Collaboration Period. The term of this Agreement may
be extended for additional periods from time to time upon mutual agreement of
the Parties hereto.

         9.2 TERMINATION FOR DEFAULT. In the event that either party to this
Agreement shall be in default of any of its material obligations hereunder and
shall fail to remedy such default within thirty (30) days after receipt of
written notice thereof, the party not in default shall have the option of
terminating this Agreement by giving written notice thereof, notwithstanding
anything to the contrary contained in this Agreement.

10.      ACCRUED RIGHTS; SURVIVING OBLIGATIONS.

         10.1 Termination of this Agreement shall not affect any accrued rights
of either party. The terms of Sections 4.2, 8.3 and 8.4 and Articles 6 and 7 of
this Agreement shall survive termination of this Agreement. Promptly after
termination of this Agreement each party shall return or dispose of any
materials and information of the other in accordance with the instructions of
the other, including without limitation any compounds provided by Terrapin
hereunder and written materials disclosed hereunder.

11.      GOVERNING LAW; DISPUTE RESOLUTION.

         11.1 GOVERNING LAW. This Agreement shall be governed by and construed
in accordance with the laws of the State of California without giving effect to
any choice or conflict

                                       7
<PAGE>

of law provision or rule that would cause the application of the laws of any
jurisdiction other than the State of California.

         11.2 DISPUTE RESOLUTION. In the event of any controversy or claim
arising out of, relating to or in connection with any provision of this
Agreement, the parties shall try to settle their differences amicably and in
good faith between themselves first, by referring the disputed matter to the
respective heads of research of each party and, if not resolved by the research
heads, by referring the disputed matter to the respective Chief Executive
Officers of each party.

12.      MISCELLANEOUS.

         12.1 NOTICES. All notices required or permitted to be given under this
Agreement shall be in writing and shall be mailed by registered or certified
airmail, postage prepaid, addressed to the signatory to whom such notice is
required or permitted to be given or transmitted by facsimile to the number
indicated below. All notices shall be deemed to have been given when mailed, as
evidenced by the postmark at the point of mailing, or transmitted by facsimile.

All notices to Genaissance shall be addressed as follows:

         Genaissance Pharmaceuticals, Inc.
         Five Science Park
         New Haven, CT 06511
         Fax: (203) 562-9377

         with a copy to:

         Michael Lytton
         Palmer & Dodge
         One Beacon Street
         Boston, MA 02108-3190
         Fax: (617) 227-4420

All notices to Terrapin shall be addressed as follows:

         Terrapin Technologies, Inc.
         750 Gateway Boulevard
         South San Francisco, California 94080
         Attention: President
         Fax: (650) 244-9240

         with a copy to:

         Cooley Godward LLP
         Five Palo Alto Square
         3000 El Camino Real
         Palo Alto, California 94306
         Attention: Brian C. Cunningham, Esq.
         Fax: (650) 857-0663

                                       8
<PAGE>

Any party may, by written notice to the other, designate a new addressee,
address or facsimile number to which notices to the party giving the notice
shall thereafter be mailed or faxed.

         12.2 INDEPENDENT CONTRACTORS. The parties shall perform their
obligations under this Agreement as independent contractors and nothing
contained in this Agreement shall be construed to be inconsistent with such
relationship status. This Agreement shall not constitute, create or in any way
be interpreted as a joint venture or partnership of any kind.

         12.3 ENTIRE AGREEMENT; AMENDMENT. This Agreement sets forth all the
covenants, promises, agreements, warranties, representations, conditions and
understandings between the parties hereto and supersedes and terminates all
prior agreements and understandings between the parties hereto with regard to
the subject matter hereof, and there are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or
written, between the parties hereto other than as set forth herein. No
subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the parties hereto unless reduced to writing and signed by the
respective authorized officers of the parties hereto.

         12.4 AFFILIATES; ASSIGNMENT. Except as otherwise provided in this
Section 12.4, neither party may assign its rights or obligations under this
Agreement without the prior written consent of the other party, such consent not
to be unreasonably withheld, except that a party may assign its rights or
obligations to a third party in connection with the merger, consolidation,
reorganization or acquisition of stock or assets affecting substantially all of
the assets or actual voting control of the assigning party. This Agreement shall
be binding upon the successors and permitted assigns of the parties. Any
attempted delegation or assignment not in accordance with this Section 12.4
shall be of no force or effect.

         12.5 HEADINGS. The headings used in this Agreement are for convenience
of reference only and are not intended to be a part of or to affect the meaning
or interpretation of this Agreement.

         12.6 FORCE MAJEURE. Any delays in performance by any party under this
Agreement shall not be considered a breach of this Agreement if and to the
extent caused by occurrences beyond the reasonable control of the party
affected, including but not limited to, acts of God, embargoes, governmental
restrictions, strikes or other concerted acts of workers, fire, flood,
explosion, riots, wars, civil disorder, rebellion or sabotage. The party
suffering such occurrence shall immediately notify the other party and any time
for performance hereunder shall be extended by the actual time of delay caused
by the occurrence.

         12.7 SEVERABILITY. If any term, condition or provision of this
Agreement is held to be unenforceable for any reason, it shall, if possible, be
interpreted rather than voided, in order to achieve the intent of the parties to
this Agreement to the extent possible. In any event, all other terms, conditions
and provisions of this agreement shall be deemed valid and enforceable to the
full extent.

         12.8 WAIVER. None of the terms, covenants, and conditions of this
Agreement can be waived except by the written consent of the party waiving
compliance.

                                       9
<PAGE>

         12.9 ENGLISH LANGUAGE. This Agreement has been prepared in the English
language and shall be construed in the English language.

         IN WITNESS WHEREOF, the parties have by duly authorized persons,
executed this Agreement, as of the date first above written.

GENAISSANCE PHARMACEUTICALS, INC.              TERRAPIN TECHNOLOGIES, INC.

By:  /s/ GUALBERTO RUANO                        By:  /s/ CLIFFORD ORENT
    ------------------------------                  ---------------------------
Printed Name:  GUALBERTO RUANO                  Printed Name:  CLIFFORD ORENT
              --------------------                            -----------------
Title:  CHIEF EXECUTIVE OFFICER                 Title:  CHAIRMAN & CEO
       ---------------------------                     ------------------------
Date:      11 FEBRUARY 1998                     Date:   FEBRUARY 11, 1998
       ---------------------------                     ------------------------<PAGE>

                                                                    EXHIBIT 10.9

                             FIRST AMENDMENT TO THE
                             COLLABORATION AGREEMENT

This first Amendment to the Collaboration Agreement (this "First Amendment") is
made and dated February 11, 1999 (the "First Amendment Effective Date") by and
between Telik, Inc. of 750 Gateway Boulevard, South San Francisco, CA 94080, a
Delaware corporation formerly known as Terrapin Technologies, Inc. ("Telik") and
Genaissance Pharmaceuticals, Inc., a Delaware corporation with its offices at
Five Science Park, New Haven, CT 06511 ("Genaissance"). Genaissance and Telik
are sometimes referred to herein individually as a "Party" and collectively as
the "Parties."

                                    RECITALS

         A. The Parties are signatories to that Collaboration Agreement dated as
of February 11, 1998 (the "Agreement").

         B. The Parties wish to make certain changes to the Agreement.

                  NOW, THEREFORE, in consideration of the above recitals the
Parties agree to amend the Agreement as follows:

1. Each reference in the Agreement to "Terrapin Technologies, Inc." is amended
and replaced by "Telik, Inc." and each reference in the Agreement to "Terrapin"
is amended and replaced by "Telik".

2. Amend Section 3.8 by deleting "twelve (12) month" and inserting in its place
"eighteen (18) month".

3. Unless otherwise expressly provided herein, defined terms used in this First
Amendment shall have the same meaning as set forth in the Agreement, and all
terms herein shall be incorporated into the Agreement. From and after the First
Amendment Effective Date, all references to the "Agreement" in all other
documents delivered in connection with the Agreement shall refer to the
Agreement, as amended hereby.

4. This First Amendment may be executed in counterparts and by facsimile.

         IN WITNESS WHEREOF, the parties have executed this First Amendment and
Extension effective as of the date set forth above.

GENAISSANCE PHARMACEUTICALS, INC.              TELIK, INC.

By:  /s/ GUALBERTO RUANO                       By:  /s/ REINALDO F. GOMEZ
    -----------------------------                  -----------------------------
Printed Name:  GUALBERTO RUANO                 Printed Name:  REINALDO F. GOMEZ
              -------------------                            -------------------
Title:  CHIEF EXECUTIVE OFFICER                Title:  VP CORPORATE ALLIANCES
       --------------------------                     --------------------------
Date:          2/19/99                         Date:          2/19/99
       --------------------------                     --------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00008-of-00352.parquet"}]]